Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline

Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline

Quick Read Ocugen (OCGN) completed enrollment of 140 patients in its Phase 3 retinitis pigmentosa trial for OCU400, with topline data expected in Q1 2027 and a rolling BLA submission targeted for Q3 2026. The company’s pipeline addresses rare blinding diseases with no approved treatments, including geographic atrophy where existing therapies generate over $1B annually but require frequent injections, while Ocugen’s one-time gene therapy approac…

Ocugen completes enrollment in liMeliGhT phase 3 trial of OCU400 for retinitis pigmentosa

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy

MALVERN, PA — Ocugen, Inc. (Nasdaq: OCGN) announced it has completed enrollment for the Phase 3 liMeliGhT clinical trial evaluating OCU400, a gene therapy candidate for retinitis pigmentosa, a group of inherited retinal disorders that can lead to vision loss. The one-year trial enrolled 140 patients and is expected to produce topline results in the first quarter of 2027, which the company said could support a biologics license application with t…